HRTX — Heron Therapeutics, Inc. Dilution Risk Tracker

Heron Therapeutics, Inc. (HRTX) has a DilutionScore of 56/100, placing it in the High dilution risk tier. This score reflects at least one active dilution mechanism — a shelf registration, ATM program, outstanding warrants, or limited cash runway — that could materially increase the share count over the next 12–18 months. Score as of July 14, 2026, updated from SEC EDGAR data.

DilutionWatch tracks 220,164 outstanding warrants for HRTX. Warrants become dilutive when exercised — converting to common shares at the strike price. Warrants near or in-the-money deserve particular attention since exercise can add materially to the outstanding share count within a short window. Cash runway is a key watch item: HRTX has approximately 7 months of runway at current burn rate. Companies with less than 18 months of runway are statistically more likely to file new shelf registrations or ATM programs within the next two quarters. DilutionWatch monitors SEC 10-Q filings to update this estimate each quarter.

DilutionWatch tracks over 25 SEC filing types for HRTX in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for HRTX alongside comparable high-risk stocks. Not financial advice — this analysis is for informational purposes only.